TEKAMLO - (150MG;5MG, 150MG;10MG, 300MG;5MG, 300MG;10MG ; Tablet)

Generic Name	ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE	**Innovator**	Novartis
Dosage	150MG;5MG, 150MG;10MG, 300MG;5MG, 300MG;10MG ; Tablet	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	Tekamlo is a combination of aliskiren, a renin inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, indicated for the treatment of hypertension, to lower blood pressure: ? As initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals. ? In patients not adequately controlled with monotherapy. ? As a substitute for its titrated components.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.